Novo Nordisk’s high-dose Wegovy increases weight loss and …
1 day ago · Novo Nordisk has commenced the STEP UP and STEP UP T2D trials to explore the efficacy of semaglutide 7.2mg. ... the higher dose of Wegovy led to a weight loss of 18.7%, surpassing the 15.6% ...
Trial shows high-dose Wegovy can increase weight loss effects
19 hours ago · Results from the STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for. Novo Nordisk has announced topline results from the phase 3b trial STEP UP, which investigated the effects of two doses of Wegovy (semaglutide) in over 1,400 patients over the course of 72 weeks.
News Details - novonordisk.com
4 days ago · Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence. Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss …
2 days ago · “We are very pleased to demonstrate 20.7% weight loss and to see that 33% of patients achieved more than 25% weight loss with semaglutide 7.2 mg, with a safety and tolerability profile comparable to semaglutide 2.4 mg,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk.
Prescription Weight Loss Medication | Wegovy® (semaglutide) …
Learn how Wegovy® (semaglutide) can help adults with obesity or excess weight with weight related conditions. Read Important Safety and Prescribing Info, including Boxed Warning.
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
4 days ago · Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival ...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial - Forbes
Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight …
Dec 20, 2024 · Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial. The new drug, CagriSema, led patients to lose 22.7% of their body...
Novo Nordisk says higher Wegovy dose caused over 20% weight loss …
Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy led to 20.7% weight loss over 72 weeks compared to 17.5% weight loss ...